Background: The objectives of this study were to assess the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) as neoadjuvant therapy before liver transplantation (LT) for advanced-stage hepatocellular carcinoma (HCC) and to analyze the prognostic factors.
Aim: To determine whether DEB-TACE before LT is superior to LT for advanced-stage HCC.
Methods: A total of 99 individuals diagnosed with advanced HCC were studied retrospectively.